Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Obesity Surgery
Erschienen in: Obesity Surgery 11/2011

01.11.2011 | Review

The Two Major Epidemics of the Twenty-First Century: Obesity and Cancer

verfasst von: Orit Kaidar-Person, Gil Bar-Sela, Benjamin Person

Erschienen in: Obesity Surgery | Ausgabe 11/2011

Einloggen, um Zugang zu erhalten

Abstract

It is a well-known fact that severe obesity is associated with the metabolic syndrome, type 2 diabetes, cardiovascular disease, hypertension, and other diseases. Epidemiological studies have suggested that obesity is also associated with increased risk of several cancer types. The number of people who are suffering from severe obesity is growing, and clinical data suggest that severely obese patients belong to a unique population with regards to risk, efficacy of screening, and cancer treatment. This review will point out the potential mechanism linking obesity and cancer and will discuss several challenges in various treatment modalities of cancer in obese patients.
Literatur
1.
Padidar S, Farquharson AJ, Williams LM, et al. Leptin upregulates pro-inflammatory cytokines in discrete cells within mouse colon. J Cell Physiol. 2011;226(8):2123–30.PubMedCrossRef
2.
Rahmati-Yamchi M, Zarghami N, Rahbani M, et al. Plasma leptin, hTERT gene expression, and anthropometric measures in obese and non-obese women with breast cancer. Breast Cancer (Auckl). 2011;5:27–35.
3.
Key TJ. Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids. 2011;76(8):812–5.PubMedCrossRef
4.
Calle EE, Rodriquez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.PubMedCrossRef
5.
Pan SY, DesMeules M. Energy intake, physical activity, energy balance, and cancer: epidemiologic evidence. Methods Mol Biol. 2009;472:191–215.PubMedCrossRef
6.
Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–91.PubMedCrossRef
7.
Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95:1218–26.PubMedCrossRef
8.
Cleary MP, Grossmann ME. Minireview: obesity and breast cancer: the estrogen connection. Endocrinology. 2009;150:2537–42.PubMedCrossRef
9.
Kabat GC, Kim M, Chlebowski RT, et al. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:2046–53.PubMedCrossRef
10.
Seewaldt VL, Goldenberg V, Jones LW, et al. Overweight and obese perimenopausal and postmenopausal women exhibit increased abnormal mammary epithelial cytology. Cancer Epidemiol Biomarkers Prev. 2007;16:613–6.PubMedCrossRef
11.
Silva TC, Barrett-Connor E, Ramires JA, et al. Obesity, estrone, and coronary artery disease in postmenopausal women. Maturitas. 2008;59:242–8.PubMedCrossRef
12.
Helzlsouer KJ, Alberg AJ, Bush TL, et al. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev. 1994;18(2):79–85.PubMed
13.
Rosenberg CR, Pasternack BS, Shore RE, et al. Premenopausal estradiol levels and the risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am J Epidemiol. 1994;140(6):518–25.PubMed
14.
Thomas HV, Key TJ, Allen DS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer. 1997;76(3):401–5.PubMedCrossRef
15.
Kabuto M, Akiba S, Stevens RG, et al. A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev. 2000;9(6):575–9.PubMed
16.
Micheli A, Muti P, Secreto G, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer. 2004;112(2):312–8.PubMedCrossRef
17.
Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2005;97(10):755–65.PubMedCrossRef
18.
Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol. 2008;630:148–65.PubMedCrossRef
19.
Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia. 2002;7:3–15.PubMedCrossRef
20.
Moran LJ, Hutchison SK, Norman RJ, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011;2:CD007506.PubMed
21.
Ahmed RL, Schmitz KH, Anderson KE, et al. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006;107:28–36.PubMedCrossRef
22.
Austin H, Austin Jr JM, Partridge EE, et al. Endoometrial cancer, obesity, and body fat distribution. Cancer Res. 1991;51(2):568–72.PubMed
23.
Gerhardsson de Verdier M, Hagman U, Steineck G, et al. Diet, body mass and colorectal cancer: a case-referent study in Stockholm. Int J Cancer. 1990;46:832–8.PubMedCrossRef
24.
Dietz AT, Newcomb PA, Marcus PM, et al. The association of body size and large bowel cancer risk in Wisconsin (United States) women. Cancer Causes Control. 1995;6:30–6.PubMedCrossRef
25.
Caan BJ, Coates AO, Slattery ML, et al. Body size and the risk of colon cancer in a large case–control study. Int J Obes Relat Metab Disord. 1998;22:178–84.PubMedCrossRef
26.
Russo A, Franceschi S, La Vecchia C, et al. Body size and colorectal-cancer risk. Int J Cancer. 1998;78:161–5.PubMedCrossRef
27.
Murphy TK, Calle EE, Rodriguez C, et al. Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol. 2000;152:847–54.PubMedCrossRef
28.
Terry PD, Miller AB, Rohan TE. Obesity and colorectal cancer risk in women. Gut. 2002;51:191–4.PubMedCrossRef
29.
Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98:920–31.PubMedCrossRef
30.
Center MM, Jemal A, Smith RA, et al. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–78.PubMedCrossRef
31.
Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res. 2002;10 Suppl 2:97S–104S.PubMedCrossRef
32.
Garow D. Metabolic syndrome is a risk factor for colorectal cancer in the United States. American College of Gastroenterology 2008 Annual Scientific Meeting. October 6, 2008.
33.
34.
Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.PubMedCrossRef
35.
Saydah SH, Platz EA, Rifai N, et al. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12:412–8.PubMed
36.
Ma J, Giovannucci E, Pollak M, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst. 2004;96:546–53.PubMedCrossRef
37.
Wei EK, Ma J, Pollak MN, et al. C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev. 2006;15:750–5.PubMedCrossRef
38.
Gunter MJ, Leitzman MF. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem. 2006;17:145–56.PubMedCrossRef
39.
Trevisan M, Liu J, Muti P, et al. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev. 2001;10:937–41.PubMed
40.
Stocks T, Lukanova A, Johansson M, et al. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond). 2008;32:304–14.CrossRef
41.
42.
Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165:1267–73.PubMedCrossRef
43.
Madarnas Y, Sawka CA, Franssen E, et al. Are medical oncologists biased in their treatment of the large woman with breast cancer? Breast Cancer Res Treat. 2001;66:123–33.PubMedCrossRef
44.
Abdah-Bortnyak R, Tsalic M, Haim N. Actual body weight for determining doses of chemotherapy in obese cancer patients: evaluation of treatment tolerability. Med Oncol. 2003;20:363–8.PubMedCrossRef
45.
Rosner GL, Hargis JB, Hollis DR, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from Cancer and Leukemia Group B Study 8541. J Clin Oncol. 1996;14:3000–8.PubMed
46.
Schwartz J, Toste B, Dizon DS. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA) > 2 m2. Gynecol Oncol. 2009;114:53–6.PubMedCrossRef
47.
Wright JD, Tian C, Mutch DG, et al. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109:353–8.PubMedCrossRef
48.
Herrington JD, Tran HT, Riggs MW. Prospective evaluation of carboplatin AUC dosing in patients with a BMI > or =27 or cachexia. Cancer Chemother Pharmacol. 2006;57:241–7.PubMedCrossRef
49.
Jenkins P, Elyan S, Freeman S. Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. Eur J Cancer. 2007;43:544–8.PubMedCrossRef
50.
Pettengell R, Schwenkglenks M, Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol. 2008;87:429–30.PubMedCrossRef
51.
Ludwig MS, McNeese MD, Buchholz TA, et al. The lateral decubitus breast boost: description, rationale, and efficacy. Int J Radiat Oncol Biol Phys. 2010;76:100–3.PubMedCrossRef
52.
Wong JR, Gao Z, Merrick S, et al. Potential for higher treatment failure in obese patients: correlation of elevated body mass index and increased daily prostate deviations from the radiation beam isocenters in an analysis of 1,465 computed tomographic images. Int J Radiat Oncol Biol Phys. 2009;75:49–55.PubMedCrossRef
53.
Soran A, Wu WC, Dirican A, et al. Estimating the probability of lymphedema after breast cancer surgery. Am J Clin Oncol. 2011 (in press).
54.
Benoist S, Panis Y, Alves A, et al. Impact of obesity on surgical outcomes after colorectal resection. Am J Surg. 2000;179:275–81.PubMedCrossRef
55.
Healy LA, Ryan AM, Sutton E, et al. Impact of obesity on surgical and oncological outcomes in the management of colorectal cancer. Int J Colorectal Dis. 2010;25:1293–9.PubMedCrossRef
56.
Grotenhuis BA, Wijnhoven BP, Hötte GJ, et al. Prognostic value of body mass index on short-term and long-term outcome after resection of esophageal cancer. World J Surg. 2010;34:2621–7.PubMedCrossRef
57.
Tsai S, Choti MA, Assumpcao L, et al. Impact of obesity on perioperative outcomes and survival following pancreaticoduodenectomy for pancreatic cancer: a large single-institution study. J Gastrointest Surg. 2010;14:1143–50.PubMedCrossRef
58.
Merkow RP, Bilimoria KY, McCarter MD, et al. Effect of body mass index on short-term outcomes after colectomy for cancer. J Am Coll Surg. 2009;208:53–61.PubMedCrossRef
59.
Lascano CA, Kaidar-Person O, Szomstein S, et al. Challenges of laparoscopic colectomy in the obese patient: a review. Am J Surg. 2006;192:357–65.PubMedCrossRef
60.
Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004;22:648–57.PubMedCrossRef
61.
You JF, Tang R, Changchien CR, et al. Effect of body mass index on the outcome of patients with rectal cancer receiving curative anterior resection: disparity between the upper and lower rectum. Ann Surg. 2009;249:783–7.PubMedCrossRef
62.
Al-Refaie WB, Parsons HM, Henderson WG, et al. Body mass index and major cancer surgery outcomes: lack of association or need for alternative measurements of obesity? Ann Surg Oncol. 2010;17:2264–73.PubMedCrossRef
63.
Ramsey AM, Martin RC. Body mass index and outcomes from pancreatic resection: a review and meta-analysis. J Gastrointest Surg. 2011 (in press).
64.
65.
Rapp K, Klenk J, Ulmer H, et al. Weight change and cancer risk in a cohort of more than 65,000 adults in Austria. Ann Oncol. 2008;19:641–8.PubMedCrossRef
66.
Van Horn L, Vitolins MZ, Wactawski-Wende J, et al. Low fat dietary pattern and risk of invasive breast cancer: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295:629–42.PubMedCrossRef
67.
Tinker LF, Bonds DE, Margolis KL, et al. Women’s Health Initiative: low fat dietary pattern and risk of treated diabetes mellitus in postmenopausal women: the Women’s Health Initiative randomized controlled dietary modification trial. Arch Intern Med. 2008;168:1500–11.PubMedCrossRef
68.
Howard BV, Van Horn L, Hsia J, et al. Low fat dietary pattern and risk of cardiovascular disease: the Women’s Health Initiative Randomised Controlled Dietary Modification Trial. JAMA. 2006;295:655–66.PubMedCrossRef
69.
Eliassen AH, Colditz GA, Rosner B, et al. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006;296:193–201.PubMedCrossRef
70.
Ashrafian H, Ahmed K, Rowland SP, et al. Metabolic surgery and cancer: protective effects of bariatric procedures. Cancer. 2011;117(9):1788–99.PubMedCrossRef
71.
Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753–61.PubMedCrossRef
72.
Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.PubMedCrossRef
Metadaten
Titel
The Two Major Epidemics of the Twenty-First Century: Obesity and Cancer
verfasst von
Orit Kaidar-Person
Gil Bar-Sela
Benjamin Person
Publikationsdatum
01.11.2011
Verlag
Springer-Verlag
Erschienen in
Obesity Surgery / Ausgabe 11/2011
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-011-0490-2

Weitere Artikel der Ausgabe 11/2011

Obesity Surgery 11/2011 Zur Ausgabe

Clinical Report

Randomized Clinical Trial of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy for the Management of Patients with BMI < 50 kg/m2

Letter to the Editor

Gastric Emptying After Sleeve Gastrectomy

Erratum

Erratum to: Are We Pricing Ourselves Out of the Market in Bariatric Surgery?

Letter to the Editor

Reply to Gastric Emptying After Sleeve Gastrectomy (OBSU-D-11-00201)

Animal Research

A Comparative Study of Gastric Banding and Sleeve Gastrectomy in an Obese Diabetic Rat Model

Clinical Research

A 5-Year Experience with Laparoscopic Adjustable Gastric Banding—Focus on Outcomes, Complications, and Their Management

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.